Bruce C. Cozadd - Dec 1, 2021 Form 4 Insider Report for Jazz Pharmaceuticals plc (JAZZ)

Role
Chairman & CEO, Director
Signature
By: /s/Paz Dizon, as attorney in fact For: Bruce C Cozadd
Stock symbol
JAZZ
Transactions as of
Dec 1, 2021
Transactions value $
-$373,475
Form type
4
Date filed
12/3/2021, 03:52 PM
Previous filing
Nov 3, 2021
Next filing
Jan 5, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JAZZ Ordinary Shares Options Exercise $454K +9.7K +3.07% $46.83 325K Dec 1, 2021 Direct
transaction JAZZ Ordinary Shares Sale -$488K -3.99K -1.23% $122.38 321K Dec 1, 2021 Direct F1, F2
transaction JAZZ Ordinary Shares Sale -$339K -2.76K -0.86% $123.06 319K Dec 1, 2021 Direct F1, F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JAZZ Non-Qualified Stock Option (right to buy) Options Exercise $0 -9.7K -11.12% $0.00 77.5K Dec 1, 2021 Ordinary Shares 9.7K $46.83 Direct F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options.
F2 Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $121.81 to $122.80. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F3 Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $121.81 to $123.43. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F4 Includes 63 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2021.
F5 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F6 This Non-qualified stock option is part of an option granted on August 9, 2012. The ordinary shares subject to this option vested over 4 years from the grant date with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter and were fully vested as of August 9, 2016.